

高雄市南屏癌症防治衛教學會

The Precision Paradigm: Unlocking Next-Gen IO Synergy in GC & ESCC

時間:2026/08/19(三)

地點: 韻藏中餐廳,高雄市左營區新上里至聖路 297 號

Time	Topic	Speaker	Moderator
18:30-18:40	Opening	吳宜珍 副院長	
18:40-19:15	Bridging the Evidence Gap: Future Perspectives on Next-Gen IO in ESCC	陳彥豪 醫師	吳宜珍 副院長
19:15-19:50	The Architecture of Potency: From Next-Gen PD-1 Engineering to Redefining 1L SOC in Gastric Cancer	謝孟哲 醫師	饒坤銘 副院長
19:50-20:25	Panel Discussion: From Molecular Potency to Clinical Practice	饒坤銘 副院長 (Panel Lead) 吳宜珍 副院長 謝孟哲 醫師 陳彥豪 醫師	
20:25-20:35	Closing	饒坤銘 副院長	

陳彥豪醫師

基本資料

- 現職：高雄長庚紀念醫院血液腫瘤科學術組副教授級主治醫師
- 專科：血液腫瘤科

學經歷

- 博士：長庚大學臨床醫學研究所博士

- **醫學系：**台北醫學大學醫學系畢業
- **經歷：**
 - 高雄長庚醫院內科部住院醫師
 - 台北榮民總醫院實習醫師

專長領域

- **主要專長：**食道癌、胃癌、肝癌、膽胰系統腫瘤、乳癌、肺癌、甲狀腺癌、大腸直腸癌
- **特色醫療：**除了標準的癌症化學治療與標靶治療外，陳醫師致力於**癌症新藥臨床試驗**，擔任多項跨國與大型癌症新藥試驗的計畫主持人，並為多個院內跨科別癌症團隊（如甲狀腺癌、膽胰癌、食道癌等）的核心成員。

謝孟哲醫師

現職

義大癌治療醫院 血液腫瘤 科主任

經歷

高雄長庚紀念醫院 血液腫瘤科 主治醫師

學歷

中山醫學大學醫學系

專長

腸胃道腫瘤 頭頸部腫瘤 胸腔腫瘤 臨床試驗

Abstract

Bridging the Evidence Gap: Future Perspectives on Tislelizumab in ESCC

Immune checkpoint inhibitors have transformed the treatment landscape of esophageal squamous cell carcinoma (ESCC), establishing a new standard of care across disease settings. Despite these advances, important questions remain regarding patient selection, treatment sequencing, long-term outcomes, and integration with multimodality therapy.

This session will review the evolving clinical evidence supporting Tislelizumab in ESCC, including key efficacy and safety data from pivotal studies and emerging real-world experience. Faculty will discuss the potential role of Tislelizumab across different treatment settings and explore future opportunities to optimize patient outcomes. The session will also examine current evidence gaps and unmet needs, providing perspectives on how ongoing research may further refine the use of immunotherapy in ESCC clinical practice.

The Architecture of Potency: From Tislelizumab Engineering to Redefining 1L SOC in Gastric Cancer

As immunotherapy becomes an integral component of first-line treatment for advanced gastric cancer, understanding the scientific rationale behind individual PD-1 antibodies is increasingly important. Tislelizumab was specifically engineered to minimize Fcγ receptor binding on macrophages, with the aim of reducing potential T-cell clearance and enhancing antitumor activity.

This session will explore the molecular design and pharmacologic characteristics of Tislelizumab and review the clinical evidence supporting its use in gastric cancer. Faculty will discuss key findings from pivotal studies, treatment outcomes across patient populations, and considerations for integrating immunotherapy into routine clinical practice. By connecting scientific innovation with clinical evidence, the session aims to provide insights into the evolving role of Tislelizumab in first-line gastric cancer management.

Panel Discussion: Translating Tislelizumab Evidence into Clinical Practice

With growing evidence supporting the use of Tislelizumab across gastrointestinal malignancies, clinicians are increasingly faced with questions regarding optimal patient selection, treatment implementation, and integration into existing treatment pathways.

This interactive panel discussion will bring together experts in gastrointestinal oncology to discuss how current evidence may influence daily clinical practice. Topics will include the application of

clinical trial data, management considerations, biomarker relevance, and practical experiences in ESCC and gastric cancer. Through expert dialogue and case-based discussion, participants will gain perspectives on translating emerging evidence into informed treatment decisions and addressing unmet needs in real-world practice. The session aims to foster scientific exchange and encourage discussion on the future role of Tislelizumab in gastrointestinal oncology.